Equites Radar

ABT · Abbott Laboratories

Medical DevicesUnited StatesAnalyst view: Buy

$101.95

-1.36% last session

End-of-day data · close of 2026-09-11

Mildly bearish1 bullish · 3 bearish technical signals
Consensus: Buy (1.54 from 24 analysts)
To mean target: +16.3%

Market cap

$179B

Enterprise value

$207B

Trailing P/E

34.0

Forward P/E

17.0

Dividend yield

2.0%

Beta

0.59

Avg volume

11M

Employees

122K

Daily Change %

-1.36%

5 Days Change

-2.86%

10 Days Change

-4.65%

30 Days Change

-4.09%

60 Days Change

12.83%

Month to Day Change

-3.40%

Year to Day Change

-14.45%

Analyst Outlook

Consensus ratingBuy
Recommendation mean (1–5)1.54
Covering analysts24
Mean price target$120.21
Low price target$103.00
Upside to mean target+16.3%

Analyst estimates change daily — follow the shifts on the Estimate Trends page.

Technical Analysis

RSI (14)33.7
50-day MA$105.19
200-day MA$104.80
Price vs 50-day MA-3.1%
Price vs 200-day MA-2.7%
MACD histogram-1.66
Volume vs 3-month avg0.8×
52w low $81.9852w high $133.53

Analyst sentiment over time — ABT

Rec Mean (blue, left — higher = more bullish) vs. price targets (right).

Investment Bank Ratings as of 2026-09-08

Latest call per bank · past 12 months

Citigroup

Buy

$125

+20.9% vs price
▲ raised from $112Maintains · 2026-08-14

UBS

Buy

$125

+20.9% vs price
▼ cut from $135Maintains · 2026-07-28

JP Morgan

Overweight

$120

+16.1% vs price
▲ raised from $110Maintains · 2026-07-17

Wells Fargo

Overweight

$112

+8.4% vs price
▲ raised from $109Maintains · 2026-07-17

RBC Capital

Outperform

$130

+25.8% vs price
Reiterates · 2026-07-17

Goldman Sachs

Buy

$113

+9.3% vs price
▼ cut from $121Maintains · 2026-05-31

Barclays

Overweight

$143

+38.4% vs price
▼ cut from $144Maintains · 2026-04-20

Bank of America

Buy

$120

+16.1% vs price
▼ cut from $150Maintains · 2026-04-17

Recent rating actions

DateFirmActionRatingPrice target
2026-09-08TD CowenReiteratesBuy$135
2026-08-25TD CowenMaintainsBuy$115 $135
2026-08-21TD CowenMaintainsBuy$115 $135
2026-08-14CitigroupMaintainsBuy$112 $125
2026-08-13Wolfe ResearchUpgradePeer PerformOutperform$0.00 $130
2026-07-28UBSMaintainsBuy$135 $125
2026-07-17CitigroupMaintainsBuy$108 $112
2026-07-17Piper SandlerReiteratesOverweight$115 $118

Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.

Signal Summary as of 2026-09-11

  • RSI (14): RSI is 34 — neutral momentum, neither overbought nor oversold.
  • Price vs 50-day MA: Trading 3.1% below the 50-day MA ($105.19).
  • Price vs 200-day MA: Trading 2.7% below the 200-day MA ($104.80).
  • MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
  • MACD (12,26,9): MACD histogram is negative (-1.66) — short-term momentum is fading.
  • 52-week range: Price sits between the 52-week low ($81.98) and high ($133.53).

ABT Price Chart

Loading chart for ABT

Fundamentals

Revenue (TTM)$47B
EBITDA$12B
Free cash flow$7.0B
Operating cash flow$10B
Book value / share$29.54
Net Debt / EBITDA2.3
WACC8.0%
Revenue growth13.00%
Earnings growth-48.00%

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

More in Medical Devices

Screen ABT against the full market on the Radar →

Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.